Introduction
Pancreatic cancer is the fifth leading cause of cancer death and has the lowest survival rate of any solid cancer in the industrialized countries [
1,
2]. In the past 20 years, 6942 Japanese patients with pancreatic cancer who underwent pancreatectomy showed a very poor prognosis with an overall median survival time (MST) of 11.7 months and a 5-year survival rate of 13.4% [
1]. Extensive molecular analysis of pancreatic cancer has led to discoveries of genetic, epigenetic and, more recently, microRNA alterations [
3‐
6].
MicroRNAs (miRNAs) are endogenous, small non-coding RNAs of 14-24 nucleotides that can negatively regulate protein expression at the post-transcriptional level by translational inhibition and/or mRNA degradation, mostly through base pairing with the 3'-UTR of their target mRNAs [
7]. Recently, the abnormal expression of miRNAs was shown to be correlated with cancer. The first evidence suggesting a direct link between miRNAs and human cancer was the localization of
miR-15a and
miR-16-1 within a 30 kb region of minimal loss on chromosome 13 that is deleted in chronic lymphocytic leukemia (CLL) and that both genes are often deleted or down-regulated in CLL [
8]. Other miRNAs, such as
miR-143 and
miR-145 have reduced levels of expression in adenomatous and cancerous stages of colorectal neoplasia [
9], while
let-7 expression is reduced in lung tumor [
10]. The first oncogenic miRNAs (oncomiR-1), the miR-17-92 cluster, named from the research on human B cell lymphomas [
11], were described as tumor suppressors or oncogenes and brought a novel area of investigation to cancer research [
12,
13].
Recently, it has been reported that
miR-200c is a marker of aggressiveness and chemoresistance in female reproductive cancers, that
miR-200c suppresses invasiveness and restores sensitivity to microtubule-targeting chemotherautic agents in breast and ovrian cancer cells, and that downregulation of
miR-200c links breast cancer stem cells with normal stem cells [
14‐
16]. Meanwhile, Hurteau
et al. revealed that over-expression of
miR-200c leads to reduced expression of
transcription factor 8 (
TCF8; also termed
ZEB1) and increased expression of
E-cadherin in breast cancer cells [
17,
18]. Also, Park
et al. reported that
miR-200c regulates epithelial to mesenchymal transition (EMT) and restores expression of
E-cadherin in breast and ovarian cancer cells [
18‐
20]. EMT is a central process in the progression of primary tumors toward metastasis (a switch from the polarized, epithelial phenotype to a highly motile fibroblastoid or mesenchymal phenotype). Furthermore, expression of
E-cadherin can predict disease outcome in patients with resectable pancreatic carcinoma, and the therapeutic restoration of
E-cadherin was proposed as a strategy to suppress cancer metastasis [
21‐
24].
In the present study, to identify novel relationship between E-cadherin and miR-200c in pancreatic cancer, we quantified miR-200c expression in a panel of 14 pancreatic cancer cell lines and in 99 samples of macro-dissected formalin-fixed paraffin-embedded (FFPE) pancreatic tissues. We also investigated the in vitro effects of miR-200c upregulation on the proliferation and invasion of pancreatic cancer cells. We found that patients with high levels of miR-200c expression had significantly better survival rates compared to those with low levels of miR-200c expression. We also found striking correlation between with the levels of miR-200c and E-cadherin expression. These data suggest that miR-200c may be a novel marker for the prognosis of pancreatic cancer.
Materials and methods
Cultured cells
The following 15 pancreatic cancer cell lines were studied: AsPC-1, KP-1N, KP-2, KP-3, PANC-1, BxPC-3 and SUIT-2 (provided by Dr. H. Iguchi, National Shikoku Cancer Center, Matsuyama, Japan); MIA PaCa-2 (Japanese Cancer Resource Bank, Tokyo, Japan); NOR-P1 (established in our laboratory by Dr. Sato); CAPAN-1, CAPAN-2, CFPAC-1, H48N, HS766T and SW1990 (American Type Culture Collection, Manassas, VA, USA). In addition, a human pancreatic ductal epithelial cell line (HPDE, provided by Dr. Ming-Sound Tsao, University of Toronto, Toronto, Ontario, Canada) was studied. The cells were maintained as described previously [
25].
Pancreatic tissues
Our study consisted of 99 patients who underwent pancreatic resection for pancreas cancer at the Department of Surgery and Oncology, Kyushu University Hospital (Fukuoka, Japan) from 1992 to 2007. The patients comprised 64 men and 35 women with a median age of 66 years (range, 36-86 years). Survival was measured from the time of pancreatic resection and death was the endpoint. Prognosis was examined in October 2008. The median observation time for overall survival was 15 months and it ranged from 1 to 101 months. Sixty four patients died during follow-up and the other patients were alive and censored.
All resected specimens were fixed in formalin and embedded in paraffin (FFPE) for pathological diagnosis. All tissues adjacent to the specimens were evaluated histologically according to the criteria of the World Health Organization. For all cases, two pathologists were in agreement with regard to pathological features and both confirmed the diagnoses. The stage of tumors was assessed according to the Union Internationale Contre le Cancer (UICC) classification. The clinicopathological characteristics of the tumor collection are described in Table
1. Written informed consent was obtained from all patients, and the study was approved by the Ethics Committee of Kyushu University and conducted according to the Ethical Guidelines for Human Genome/Gene Research enacted by the Japanese Government and the Helsinki Declaration.
Table 1
Clinicopathological Characteristics of 99 Patients with Pancreatic Cancer
Histological diagnosis | | | |
Adenocarcinoma | | 97 (98.0%) |
Adenosquamous carcinoma | 2 (2.0%) | |
pT category | | | |
pT1 | | | 6 (6.1%) | |
pT2 | | | 3 (3.0%) | |
pT3 | | | 57 (57.6%) |
pT4 | | | 33 (33.3%) |
pN category | | | |
pN0 | | | 33 (33.3%) |
pN1 | | | 66 (66.7%) |
UICC stage | | | |
IA & IB | | | 5 (5.1%) & 4 (4.0%) |
IIA & IIB | | | 21 (21.2%) & 64 (64.7%) |
III | | | 1 (1.0%) |
IV | | | 4 (4.0%) |
Histological grade | | | |
G1 | | | 20 (20.2%) |
G2 | | | 43 (43.4%) |
G3 | | | 36 (36.4%) |
Residual tumor category | | |
R0 | | | 60 (61.2%) |
R1 | | | 38 (38.7%) |
Vessel invasion | | | |
Positive | | | 61 (62.2%) |
Negative | | | 37 (37.7%) |
Neural invasion | | | |
Positive | | | 84 (84.8%) |
Negative | | | 15 (15.2%) |
miRNA isolation
miRNAs were extracted from cultured cells using a mir Vana™ miRNA Isolation Kit (Ambion, Austin, TX, USA) and from macro-dissected FFPE pancreatic tissues using an RNeasy® FFPE Kit (Qiagen, Tokyo, Japan), following the manufacturer's instructions. Considering the influence of genomic DNA contamination, especially from the FFPE materials, Qiagen provides a special gDNA Eliminator spin column to rapidly remove genomic DNA, and we also performed a DNase digestion step. The extracted RNA was quantified by absorbance at 260 nm and its purity was evaluated by the absorbance ratio at 260/280 nm with a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Rockland, DE, USA).
Quantitative real-time reverse-transcription polymerase chain reaction (qRT-PCR)
The expression of miR-200c and RNU6B (U6 snRNA, a reference gene) was measured by qRT-PCR using a TaqMan® MicroRNA Reverse Transcription Kit and TaqMan® Universal PCR Master Mix (No AmpErase® UNG; Applied Biosystems, Tokyo, Japan) and a Chromo4™ System (Bio-Rad, Hercules, CA, USA). We followed the manufacturer's protocols to perform two-step real-time RT-PCR for the measurement of miR-200c and RNU6B expression. Each sample was run in triplicate. The level of miR-200c expression was calculated from a standard curve constructed with small RNAs from the CAPAN-1 pancreatic cancer cell line. The expression levels of miR-200c were normalized against the corresponding expression levels of RNU6B.
The levels of
E-cadherin mRNA and
18S rRNA were measured by qRT-PCR using a QuantiTect SYBR Green RT-PCR Kit (Qiagen, Tokyo, Japan) and a Chromo4™ System, following the manufacturer's protocols [
26]. Each sample was run in triplicate. We designed specific primers for
E-cadherin (forward, 5'-tcagcgtgtgtgactgtgaa-3'; reverse, 5'-aggctgtgccttcctacaga-3'), and
18S rRNA (forward, 5'-ctttcgaggccctgtaattg-3'; reverse, 5'-cctccaatggatcctcgtta-3') using Primer 3 software and performed BLAST searches to ensure the specificity of the primers. The PCR products amplified using these primers are small (
18S rRNA, 63 bp;
E-cadherin, 53 bp), which allowed accurate and sensitive qRT-PCR despite the fragmented RNA extracted from FFPE tissue specimens [
27,
28]. We also included controls without reverse transcriptase to confirm that there was no influence from genomic DNA contamination. The level of
E-cadherin mRNA was calculated from a standard curve constructed with total RNA from CAPAN-1 cells and normalized against levels of
18S rRNA. Accuracy and integrity of PCR products were confirmed with an Agilent 1000 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA).
Cell transfection with miRNA precursors
Upregulation of miR-200c expression was achieved by transfection with the hsa-miR-200c precursor (Pre-miR™ miRNA Precursor; Applied Biosystems). To verify the specificity of the transfection effect, we used a Pre-miR™ miRNA Precursor Negative Control (Applied Biosystems). Transfections were performed by electroporation using a Nucleofector system (Amaxa Biosystems, Köln, Germany) according to the manufacturer's instructions. PANC-1, SUIT-2 and KP-2 cells (1-2 × 106) were transfected with 100 pmol of the indicated precursor or negative control. The degree of mature miR-200c upregulation 48 h after transfection was verified by quantifying the expression level of mature miR-200c. Cells harvested 48 h after transfection were also used for cell proliferation or invasion assays.
Propidium iodide (PI) assay
Cell proliferation was evaluated using a multiwell fluorescence plate reader and a previously described method [
29] with modifications [
30,
31]. Briefly, cancer cells were seeded at 2 × 10
4 cells/well in Falcon flat-bottom 24-well plates (Becton Dickinson, Franklin Lakes, NJ, USA). 30 μM PI (Wako Ltd., Osaka, Japan) and 600 μM digitonin (Wako Ltd.) were then added to each well. After incubation for 90 min of at 37°C, the fluorescence intensities of labeled nuclei were measured using a CYTO Fluor™ II fluorescence multiwell plate reader (PerSeptive Biosystems, Framingham, MA, USA) to determine total cell numbers.
In vitro Matrigel invasion assay
Invasion of pancreatic cancer cells was evaluated by the numbers of cells invading Matrigel-coated transwell inserts (Becton Dickinson) as reported previously [
25,
32]. Briefly, transwell inserts with 8 μm pores were coated with Matrigel (20 μg/well; Becton Dickinson). Cancer cells were seeded in the upper chamber at a density of 1.0 × 10
5 cells/cm
2 in 250 μl of Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS). After incubation at 37°C, cells that had invaded to the lower surface of the Matrigel-coated membranes were fixed with 70% ethanol, stained with hematoxylin and eosin (H & E) and counted in five randomly selected fields under a light microscope.
Statistical analysis
The
in vitro data are presented as mean values with error bars representing the minimum and maximum or with the standard deviation (SD). The significance level was
p < 0.05.
MiR-200c expression in macro-dissected FFPE samples was split into high and low expression groups using a recursive descent partition analysis. Categorical variables were compared with the chi-square test (Fisher's exact probability test). Survival curves were constructed with the Kaplan-Meier product-limit method and compared by log-rank tests. To evaluate independent prognostic factors associated with survival, a multivariate Cox proportional hazards regression analysis was used, with
miR-200c expression, age, sex pathological tumor (pT) status, pathological node (pN) status, UICC stage, residual tumor (R) status, histological grade (G) and vessel invasion as covariates (Table
2). Statistical significance was defined as
p < 0.05. The statistical analyses in the macro-dissected FFPE samples were performed with JMP 7.01 software (SAS Institute, Cary, NC, USA).
Table 2
Univariate and Multivariate Survival Analyses
Age (< 65) | 0.9 | 0.5 - 1.4 | 0.62 | 0.8 | 0.5 - 1.4 | 0.50 |
Sex(Female) | 0.9 | 0.5 - 1.5 | 0.63 | 0.9 | 0.5 - 1.6 | 0.69 |
pT (pT1/2) | 2.2 | 1.4 - 3.6 | < 0.001 | 1.8 | 0.5 - 5.4 | 0.35 |
pN (negative) | 0.4 | 0.2 - 0.7 | < 0.001 | 0.5 | 0.3 - 1.0 | 0.06 |
UICC stage | - | - | 0.003 | - | - | 0.01 |
Histological grade (G3) | 1.7 | 0.9 - 2.8 | 0.07 | 0.8 | 0.6 - 2.6 | 0.8 |
Residual tumor (positive) | 3.0 | 1.8 - 5.0 | < 0.001 | 3.2 | 1.8 - 5.8 | < 0.001 |
Vessel invasion (positive) | 2.3 | 1.4 - 4.1 | 0.001 | 1.9 | 1.0 - 3.6 | 0.03 |
Low miR-200c | 1.8 | 1.0 - 3.5 | 0.03 | 2.2 | 1.1 - 4.6 | 0.02 |
Discussion
The present study shows, for the first time, the involvement of
miR-200c in pancreatic cancer progression and prognosis. We have found that high
miR-200c expression was related to low invasion ability, and that upregulation of
miR-200c expression inhibited cell invasion and stimulated cell proliferation in pancreatic cancer cell lines. We also have found a significant correlation between
miR-200c and
E-cadherin expression, and that upregulation of
miR-200c expression correlated with increased expression of
E-cadherin in pancreatic cancer cell lines. This finding is consistent with previous reports investigating other cancers [
14‐
19]. On the other hand, reduced expression of E-cadherin is regarded as a main molecular event in the dysfunction of the cell-cell adhesion system, triggering cancer invasion and metastasis [
33,
34]. Recently, Liu
et al. revealed that E-cadherin stimulated cell proliferation at intermediate seeding densities, and Mees
et al. revealed that metastasis suppressor gene EP300 was regulated by
miR-200c in ductal adenocarcinomas of the pancreas [
35,
36]. These studies indicate that
miR-200c plays a key role in the enhancement of proliferation and inhibition of invasion in pancreatic cancer via regulation of E-cadherin. Such inconsistent function is similar to gamma-interferon, which can inhibit tumor growth and enhance metastasis in a TS/A mammary adenocarcinoma model [
37].
Furthermore, univariate and multivariate analyses of 99 macro-dissected FFPE pancreatic cancer samples revealed that high
miR-200c expression was associated with a better prognosis.
E-cadherin is considered as a prognosis factor in some cancers [
38], and we also found that high
E-cadherin expression was associated with a better prognosis in univariate analyses of macro-dissected FFPE pancreatic cancer samples but not in multivariate analyses (data not shown). These findings indicate that E-cadherin can be used as a prognosis factor by immunohistochemistry to detect E-cadherin protein or by qRT-PCR to measure
E-cadherin mRNA levels. However, it is difficult to generate a highly specific E-cadherin protein antibody or specific
E-cadherin mRNA primers, especially when using fragmented RNA from FFPE samples. miRNAs are small RNAs of 14 -24 nucleotides and are more stable than mRNA from FFPE samples [
39] and the technologies of miRNA extraction and of qRT-PCR can be controlled more easily than those for mRNAs. Taken together, these findings suggest that
miR-200c can be a better independent prognosis factor than
E-cadherin mRNA in univariate or multivariate analyses, while the latter can be used as a prognosis factor in univariate analyses only. Furthermore, Mitchell,
et al. reported that circulating miRNAs are stable blood-based markers for cancer detection [
40], suggesting that quantifying the levels of
miR-200c from patients' pancreatic juice or blood may provide an important marker for indicating the suitability for surgery.
In conclusion, our results have revealed that high levels of
miR-200c expression inhibit cancer invasion and stimulate cancer cell proliferation, possibly via up-regulation of
E-cadherin, and that high levels of
miR-200c expression correlate with better survival of patients with curative resection of pancreatic cancer. We believe that research into
miR-200c may bring about new opportunities for the development of drugs and therapeutic strategies for the treatment of pancreatic cancer. On the other hand, the
miR-200 family members, like
miR-200a/b/c,
miR-141, and
miR-429, have similar, but not identical functions ([
19,
20] and [
36]). We believe that it is necessary to investigate the other family members to complete the picture regarding the
miR-200 family and pancreatic cancer.
Acknowledgements
We thank Miyuki Ohmori for expert technical assistance in preparing the FFPE sections for macro-dissection and Emiko Manabe and Midori Sato for their help in maintaining the cell line cultures and handling the clinical samples.
Financial support
This project was supported by A Grant-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and grants from the Kato Memorial Bioscience Foundation.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
Conception and design: JY, KO, KM, and MT; analysis and interpretation: JY, TK, and KN; data collection: HF; writing the article: JY; critical revision of the article: KO, KM, NS, and MT; final approval of the article: JY and MT; statistical analysis: JY, KO, and KN; overall responsibility: KO and KM. All authors read and approved the final manuscript.